Articles from IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 fourth quarter and full year financial results for Monday, February 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, today announced that the Company’s Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company’s common stock. Repurchases may be made at management’s discretion from time to time in the open market (including through Rule 10b5-1 plans) or in negotiated transactions. These shares are in addition to the 1.3 million shares remaining under the Company’s ongoing share repurchase program as of December 3, 2024, pursuant to previous Board authorizations. The share repurchase program has no specified expiration date and may be suspended or discontinued at any time.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon has decided to retire from IDEXX effective June 1, 2025. Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (“CAG”) Finance, will succeed Mr. McKeon as IDEXX’s Executive Vice President, Chief Financial Officer and Treasurer, effective March 1, 2025. Mr. McKeon will serve as EVP and Special Advisor to the Company from March 1, 2025 until his retirement from IDEXX on June 1, 2025, to help ensure a smooth and seamless transition.

In the 2024 Growth and Financial Performance Outlook section, second paragraph, second sentence should read: At midpoint, projected full year comparable operating profit margin expansion of 30 - 60 basis points includes a ~40 basis point negative growth impact from lapping a customer contract resolution payment in the first quarter of 2023. (instead of: At midpoint, projected full year comparable operating profit margin expansion of 70 - 100 basis points includes a ~40 basis point negative growth impact from lapping a customer contract resolution payment in the first quarter of 2023.)

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 third quarter results for Thursday, October 31, 2024, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, today announced that Jay Mazelsky, President and Chief Executive Officer, and Brian McKeon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 from 11:30 am – 12:05 pm (EDT).

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, today announced second quarter results.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, will now host its 2024 second quarter conference call and webcast at 9:00 am ET on Tuesday, August 6, 2024, to minimize conflicts with other industry earnings announcements.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 second quarter results for Tuesday, August 6, 2024, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon, Executive Vice President and Chief Financial Officer, and Michael Lane, Executive Vice President, General Manager, Reference Laboratories and Information Technology, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 29, 2024 from 10:55 am – 11:25 am (EDT).

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, today announced first quarter results.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 first quarter results for Wednesday, May 1, 2024, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences:

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2023 fourth quarter and full year financial results for Monday, February 5, 2024 before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, will participate in two upcoming institutional investor events:

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, today announced third quarter results.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2023 third quarter results for Wednesday, November 1, 2023 before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, today announced second quarter results.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, today announced the election of Irene Chang Britt, a former executive at Campbell Soup Company, to the Company's Board of Directors, effective July 11, 2023.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2023 second quarter results for Tuesday, August 1, 2023 before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, will participate in the Stifel Jaws & Paws Conference on Wednesday, May 31, 2023. Jay Mazelsky, President and Chief Executive Officer, and Brian McKeon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at 1:15 pm (EDT).

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, today announced first quarter results.

IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2023 first quarter results for Tuesday, May 2, 2023 before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.